Nirvana Life Sciences Inc.
NIRVF
$0.083
$0.0830.00%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -60.81% | -54.48% | -49.84% | -42.56% | -28.29% |
| Depreciation & Amortization | -82.63% | -60.18% | -73.58% | -80.41% | -63.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.25% | -55.06% | -50.23% | -40.02% | -27.55% |
| Operating Income | 63.25% | 55.06% | 50.23% | 40.02% | 27.55% |
| Income Before Tax | 63.53% | 52.62% | 49.17% | 25.94% | 76.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.53% | 52.62% | 49.17% | 25.94% | 76.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -80.00% | -48.57% | -42.42% | -26.67% | 2.94% |
| Net Income | 63.47% | 52.64% | 49.21% | 25.96% | 76.13% |
| EBIT | 63.25% | 55.06% | 50.23% | 40.02% | 27.55% |
| EBITDA | 62.40% | 52.64% | 49.39% | 40.05% | 27.92% |
| EPS Basic | 70.49% | 63.95% | 62.54% | 45.36% | 81.50% |
| Normalized Basic EPS | 74.48% | 66.45% | 64.49% | 42.32% | 84.97% |
| EPS Diluted | 70.49% | 63.95% | 62.54% | 45.36% | 81.50% |
| Normalized Diluted EPS | 74.48% | 66.45% | 64.49% | 42.32% | 84.97% |
| Average Basic Shares Outstanding | 11.89% | 21.92% | 33.93% | 37.61% | 31.20% |
| Average Diluted Shares Outstanding | 11.89% | 21.92% | 33.93% | 37.61% | 31.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |